[Form 4] BRISTOL MYERS SQUIBB CO Insider Trading Activity
Peter J. Arduini, a director of Bristol-Myers Squibb Company (BMY), reported acquisition of 748.337 Deferred Share Units on 09/30/2025. Each Deferred Share Unit will convert into one share of common stock upon settlement; the units become settleable when the reporting person ceases to be a director or at a previously specified future date. After this transaction the filing shows the reporting person beneficially owns 64,620.164 shares (this total includes deferred compensation and reinvested dividends under the company’s 1987 Deferred Compensation Plan for Non-Employee Directors). The Form 4 was signed by an attorney-in-fact on 10/02/2025.
Peter J. Arduini, un direttore di Bristol-Myers Squibb Company (BMY), ha riportato l'acquisizione di 748.337 Deferred Share Units il 30/09/2025. Ogni Deferred Share Unit si convertirà in una azione ordinaria al momento dell'acquisizione; le unità diventano liquidabili quando la persona che riferisce i dati cessa di essere direttore o a una data futura precedentemente specificata. Dopo questa transazione la presentazione mostra che la persona che riferisce detiene beneficiamente 64.620,164 azioni (questo totale include compensi differiti e dividendi reinvestiti secondo il Deferred Compensation Plan for Non-Employee Directors della società del 1987). Il Form 4 è stato firmato da un procuratore-in-fatto il 02/10/2025.
Peter J. Arduini, un director de Bristol-Myers Squibb Company (BMY), informó sobre la adquisición de 748.337 Unidades de Acciones Diferidas el 30/09/2025. Cada Unidad de Acción Diferida se convertirá en una acción ordinaria al momento de la liquidación; las unidades se pueden liquidar cuando la persona que informa deja de ser director o en una fecha futura especificada previamente. Después de esta operación, la presentación muestra que la persona que informa posee beneficiosamente 64.620,164 acciones (este total incluye la compensación diferida y dividendos reinvertidos conforme al plan de compensación diferida para no empleados directores de la compañía de 1987). El Formulario 4 fue firmado por un apoderado el 02/10/2025.
Peter J. Arduini는 Bristol-Myers Squibb Company (BMY)의 이사로서 748.337의 지연주식단위(Deferred Share Units)를 2025년 9월 30일에 취득했다고 보고했습니다. 각 지연주식단위는 정산 시점에 보통주 1주로 전환되며; 이 단위는 보고자가 이사직을 그만두거나 사전에 지정된 미래의 날짜에 청산 가능해집니다. 이 거래 이후 서류에 따르면 보고자는 혜택을 받은 주식 64,620.164주를 소유하고 있으며(이 총액은 회사의 1987년 비근무 이사를 위한 연기 보상 계획에 따른 연기 보상과 재투자 배당금을 포함합니다). Form 4는 2025년 10월 2일에 대리인에 의해 서명되었습니다.
Peter J. Arduini, administrateur de Bristol-Myers Squibb Company (BMY), a déclaré l'acquisition de 748.337 unités d'actions différées le 30/09/2025. Chaque unité d'actions différées se convertira en une action ordinaire à son règlement; les unités deviennent réglables lorsque la personne déclarant cesse d'être administrateur ou à une date future préalablement spécifiée. Après cette transaction, le dossier indique que la personne déclarant détient bénéficiairement 64.620.164 actions (ce total inclut la rémunération différée et les dividendes réinvestis dans le cadre du plan de rémunération différée de 1987 pour les administrateurs non salariés de l'entreprise). Le Formulaire 4 a été signé par un mandataire le 02/10/2025.
Peter J. Arduini, ein Direktor der Bristol-Myers Squibb Company (BMY), meldete den Erwerb von 748.337 Deferred Share Units am 30.09.2025. Jede Deferred Share Unit wird bei der Abrechnung in eine Aktie des Stammkapitals umgewandelt; die Einheiten werden abrechenbar, wenn die meldende Person nicht mehr Direktor ist oder zu einem zuvor festgelegten zukünftigen Datum. Nach dieser Transaktion zeigt die Einreichung, dass die meldende Person Inhaber von 64.620.164 Aktien beantragt besitzt (diese Summe umfasst abgefederte Vergütung und reinvestierte Dividenden gemäß dem 1987 Deferred Compensation Plan für Nicht-Angestellte Direktoren des Unternehmens). Das Formular 4 wurde von einem Bevollmächtigten am 02.10.2025 unterzeichnet.
Peter J. Arduini، مدير في Bristol-Myers Squibb Company (BMY)، أبلغ عن اكتساب 748.337 وحدة أسهم مؤجلة في 30/09/2025. ستتحول كل وحدة أسهم مؤجلة إلى سهم واحد من الأسهم العادية عند التسوية؛ تصبح الوحدات قابلة للتسوية عندما يتوقف الشخص المبلغ عن كونه مديراً أو في تاريخ مستقبلي محدد مسبقاً. بعد هذه المعاملة، تُظهر الإيداع أن الشخص المبلغ يملك بشكل مستفاد 64,620.164 سهماً (يشمل هذا الإجمالي التعويض المؤجل وتوزيعات الأرباح المعاد استثمارها بموجب خطة التعويض المؤجل غير الموظفين المدراء في الشركة لعام 1987). تم توقيع النموذج 4 من قبل وكيل قانوني في التاريخ 02/10/2025.
Peter J. Arduini，Bristol-Myers Squibb Company (BMY)的董事，报告在2025-09-30取得了748.337份延期股票单位（Deferred Share Units）。每份延期股票单位在结清时将转换为一股普通股；这些单位在报告人不再担任董事或在事先指定的未来日期方可结算。交易完成后，备案显示报告人受益所有64,620.164股（此总额包括公司1987年非员工董事延期报酬计划下的延期报酬与再投资的股息）。Form 4 于2025-10-02由代理签署。
- Acquisition of 748.337 Deferred Share Units shows alignment of director compensation with shareholder equity
- Total beneficial ownership of 64,620.164 shares (including plan holdings) indicates meaningful stake held by the director
- None.
Insights
Director received 748.337 deferred units that convert to shares on settlement.
The filing documents a routine director compensation event: 748.337 Deferred Share Units were acquired on 09/30/2025. These units convert 1:1 into common shares upon settlement, typically tied to exit or a pre-specified date, indicating deferred equity pay rather than open-market trading.
The report lists total beneficial ownership of 64,620.164 shares, which the company says includes amounts held under the 1987 Deferred Compensation Plan for Non-Employee Directors. This clarifies that a portion of the director’s stake reflects accrued, plan-based holdings.
Form 4 discloses a compensatory equity grant and appears procedurally complete.
The transaction is coded as an acquisition of deferred share units (compensation), not a market purchase or sale. The Form 4 shows the reporting person filed individually and the signature was provided by an attorney-in-fact on 10/02/2025.
No amendments, option exercises, or cash prices are reported; the filing contains explanatory notes about conversion and plan inclusion but no additional material disclosures.
Peter J. Arduini, un direttore di Bristol-Myers Squibb Company (BMY), ha riportato l'acquisizione di 748.337 Deferred Share Units il 30/09/2025. Ogni Deferred Share Unit si convertirà in una azione ordinaria al momento dell'acquisizione; le unità diventano liquidabili quando la persona che riferisce i dati cessa di essere direttore o a una data futura precedentemente specificata. Dopo questa transazione la presentazione mostra che la persona che riferisce detiene beneficiamente 64.620,164 azioni (questo totale include compensi differiti e dividendi reinvestiti secondo il Deferred Compensation Plan for Non-Employee Directors della società del 1987). Il Form 4 è stato firmato da un procuratore-in-fatto il 02/10/2025.
Peter J. Arduini, un director de Bristol-Myers Squibb Company (BMY), informó sobre la adquisición de 748.337 Unidades de Acciones Diferidas el 30/09/2025. Cada Unidad de Acción Diferida se convertirá en una acción ordinaria al momento de la liquidación; las unidades se pueden liquidar cuando la persona que informa deja de ser director o en una fecha futura especificada previamente. Después de esta operación, la presentación muestra que la persona que informa posee beneficiosamente 64.620,164 acciones (este total incluye la compensación diferida y dividendos reinvertidos conforme al plan de compensación diferida para no empleados directores de la compañía de 1987). El Formulario 4 fue firmado por un apoderado el 02/10/2025.
Peter J. Arduini는 Bristol-Myers Squibb Company (BMY)의 이사로서 748.337의 지연주식단위(Deferred Share Units)를 2025년 9월 30일에 취득했다고 보고했습니다. 각 지연주식단위는 정산 시점에 보통주 1주로 전환되며; 이 단위는 보고자가 이사직을 그만두거나 사전에 지정된 미래의 날짜에 청산 가능해집니다. 이 거래 이후 서류에 따르면 보고자는 혜택을 받은 주식 64,620.164주를 소유하고 있으며(이 총액은 회사의 1987년 비근무 이사를 위한 연기 보상 계획에 따른 연기 보상과 재투자 배당금을 포함합니다). Form 4는 2025년 10월 2일에 대리인에 의해 서명되었습니다.
Peter J. Arduini, administrateur de Bristol-Myers Squibb Company (BMY), a déclaré l'acquisition de 748.337 unités d'actions différées le 30/09/2025. Chaque unité d'actions différées se convertira en une action ordinaire à son règlement; les unités deviennent réglables lorsque la personne déclarant cesse d'être administrateur ou à une date future préalablement spécifiée. Après cette transaction, le dossier indique que la personne déclarant détient bénéficiairement 64.620.164 actions (ce total inclut la rémunération différée et les dividendes réinvestis dans le cadre du plan de rémunération différée de 1987 pour les administrateurs non salariés de l'entreprise). Le Formulaire 4 a été signé par un mandataire le 02/10/2025.
Peter J. Arduini, ein Direktor der Bristol-Myers Squibb Company (BMY), meldete den Erwerb von 748.337 Deferred Share Units am 30.09.2025. Jede Deferred Share Unit wird bei der Abrechnung in eine Aktie des Stammkapitals umgewandelt; die Einheiten werden abrechenbar, wenn die meldende Person nicht mehr Direktor ist oder zu einem zuvor festgelegten zukünftigen Datum. Nach dieser Transaktion zeigt die Einreichung, dass die meldende Person Inhaber von 64.620.164 Aktien beantragt besitzt (diese Summe umfasst abgefederte Vergütung und reinvestierte Dividenden gemäß dem 1987 Deferred Compensation Plan für Nicht-Angestellte Direktoren des Unternehmens). Das Formular 4 wurde von einem Bevollmächtigten am 02.10.2025 unterzeichnet.
FAQ
What did BMY director Peter J. Arduini report on Form 4?
How many Bristol-Myers Squibb (BMY) shares does the reporting person beneficially own after the transaction?
When do the Deferred Share Units become settleable?
Was the Form 4 filed jointly or by one reporting person?
Who signed the Form 4 and when?
